Stockreport

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF ? Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV? SANRECO Phase 2 Study On-Track for Complet [Read more]